This biotechnology company has seen no estimate revision in the last 7 days. Meanwhile, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if Friday’s rally can turn into more strength down the road.
Ultragenyx currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Investors interested in the biomedical industry may consider better-ranked stocks like Curis, Inc. (CRIS), Biogen Idec Inc. (BIIB) and Actelion Ltd. (ALIOF). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment